New hope for rare blood disease: gentler transplant trial seeks to replace toxic chemo

NCT ID NCT04784052

Summary

This trial is testing a new way to perform stem cell transplants for people with Fanconi anemia, a rare genetic disorder that causes bone marrow failure. The goal is to use a special, processed donor graft and an experimental antibody called JSP-191 during the pre-transplant conditioning, hoping this leads to successful engraftment with fewer and less severe side effects than standard chemotherapy. Up to 18 participants will be followed for two years to see if this approach is safe and effective.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FANCONI ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Stanford University

    RECRUITING

    Stanford, California, 94305, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.